Dr. Nordstrom’s work in the lab helps research teams learn as much as possible about cancer drugs, like how they work and important safety information, before they are provided to patients in clinical trials.
Today is Metastatic Breast Cancer Awareness Day. Visit https://t.co/PzVunk6V3B to learn about the disease that affects thousands of people both today and every day. #MetastaticBreastCancerAwarenessDay
MacroGenics honors the survivors and those we’ve lost during #BreastCancerAwareness month. We continue our work to increase research around this all-too-common disease.
We are pleased to share our clinical results from Cohort A Pt 1 of Ph 2/3 MAHOGANY study of margetuximab in combination with retifanlimab in gastroesophageal adenocarcinoma at #ESMO21 https://t.co/i3Kn3XnT3J
On Wednesday, Zai Lab Ltd. entered a deal with @MacroGenics Inc. covering up to four CD3- or CD47-based bispecifics. The expanded collaboration will give the Shanghai-based biotech broader Asia and worldwide rights to multiple cancer programs https://t.co/Tx7xdSEUfe $ZLAB $MGNX
SOPHIA trial results have been published in @JAMAOnc; these data describe a new treatment option for adults with metastatic HER2+ breast cancer. Read more here: https://t.co/UYtoB0OkP0
Living with metastatic HER2-positive breast cancer and not sure where to turn? Check out the @mbcalliance for information and support services. You can learn from others, share experiences and more: https://t.co/nZQKqJ5nmo
Scientific advances are bringing women with metastatic HER2-positive #breastcancer the benefits of cutting-edge medical innovations - but there remains unmet need, as patients’ disease progresses. #MBC
This marks the first FDA approval for MacroGenics – thank you to the patients, physicians, nurses and staff involved in the clinical trial and to our employees who’ve worked to bring important therapies to patients in need.
Today, we announced the FDA approval of a treatment option for patients living with metastatic HER2-positive #breastcancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease #MBC. Read more: https://t.co/bmZUmgqrQk